TuHURA Biosciences, Inc./NV
No SEC Form 4 filings for $HURA in the last 30 days.
See all $HURA insider activity →TuHURA Biosciences (NASDAQ:HURA) received a new U.S. patent (No. 12,760,104) for its VISTA inhibitor, TBS-2025, covering bispecific/multi-specific antibodies and expanding treatment areas. The patent extends to 2042, protecting the company's VISTA franchise and potential collaborations, according to TuHURA.
TuHURA Biosciences (NASDAQ:HURA) received a U.S. patent for its Delta Opioid Receptor (DOR) technology, covering uses in cancer treatments, including ADCs and cellular immunotherapies. The patent, valid until 2043, aims to enhance cancer immunotherapy effectiveness by targeting MDSCs. TuHURA is advancing preclinical models for blood-related cancers like AML and MDS.
TuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning HURA (TuHURA Biosciences, Inc./NV). Coverage has skewed bullish: 2 bullish, 0 neutral, and 0 bearish.
Recent HURA coverage spans corporate actions, financial news and technology.
Patent broadening strengthens IP coverage for TBS-2025 and may improve perceived value for future partnering or financing, with limited near-term clinical read-through.
The patent grants TuHURA exclusive rights to a novel immuno‑oncology platform, which could enhance its pipeline valuation.
Small financing draw; unlikely to move price materially.
Small additional financing for general corporate purposes; unlikely to move the stock materially.
The plan may dilute existing shareholders but signals intent to attract talent, modest upside for the stock.
AlphAI scores every news story that mentions HURA with an AI model for sentiment and relevance, and aggregates insider trades from TuHURA Biosciences, Inc./NV's SEC EDGAR Form 4 filings. Figures refresh continuously.
TuHURA Biosciences (NASDAQ:HURA) received a new U.S. patent (No. 12,760,104) for its VISTA inhibitor, TBS-2025, covering bispecific/multi-specific antibodies and expanding treatment areas. The patent extends to 2042, protecting the company's VISTA franchise and potential collaborations, according to TuHURA.
3 min readTuHURA Biosciences (NASDAQ:HURA) received a U.S. patent for its Delta Opioid Receptor (DOR) technology, covering uses in cancer treatments, including ADCs and cellular immunotherapies. The patent, valid until 2043, aims to enhance cancer immunotherapy effectiveness by targeting MDSCs. TuHURA is advancing preclinical models for blood-related cancers like AML and MDS.
2 min readTuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol
1 min readTuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol
1 min readTuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Adoption of the TuHURA Biosciences, Inc. 2026 Inducement Equity Incentive Plan On September 10, 2026, the Board of Director
1 min readTuHURA Biosciences (HURA) received FDA clearance for its IND application for TBS-2025, a VISTA-inhibiting monoclonal antibody for AML. The Phase 1b study will evaluate TBS-2025 in relapsed/refractory mutNPM1 AML patients. Preclinical data showed increased survival in AML models. HURA stock is up 1.71%, trading at $2.09.
2 min readTuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol
1 min readTuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. As previously disclosed, on April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Hol
1 min readTuHURA Biosciences, Inc./NV (HURA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 3.02 Unregistered Sale of Equity Securities . As previously disclosed in the Current Report on Form 8-K filed by TuHURA Biosciences, Inc. (the “Company”) with the Securities and Exchange Commission on April 22, 2026, on April 21, 2026, the Company entered into a Loan Agreeme
1 min readTuHURA Biosciences (NASDAQ:HURA) reported Q2 2026 results for the quarter ended June 30, 2026, and outlined upcoming FDA and clinical milestones. Cash was $1.0M at June 30. R&D expenses were $6.6M. The company also described a $50M non-convertible term credit facility from its largest shareholder and expected orphan drug designations and trial starts in 2H 2026-2027.
6 min read
